武田-话题@MedSci

#武田#

91篇内容 | 1668人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1517273, encodeId=f31c151e27396, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田2020财年业绩保持韧性，利润率和现金流均表现强劲；基础营收增长预计在2021财年加速, objectType=article, longId=211504, objectId=411e2115046d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=411e2115046d, replyNumber=0, likeNumber=33, createdTime=2021-05-20, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=411e2115046d, moduleTitle=武田2020财年业绩保持韧性，利润率和现金流均表现强劲；基础营收增长预计在2021财年加速, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=411e2115046d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517272, encodeId=a224151e27216, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田宣布美国FDA将优先审理Mobocertinib (TAK-788)治疗EGFR外显子20插入+转移性非小细胞肺癌的新药报批, objectType=article, longId=210637, objectId=db3b21063ea2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db3b21063ea2, replyNumber=0, likeNumber=37, createdTime=2021-05-01, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db3b21063ea2, moduleTitle=武田宣布美国FDA将优先审理Mobocertinib (TAK-788)治疗EGFR外显子20插入+转移性非小细胞肺癌的新药报批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db3b21063ea2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517271, encodeId=fe76151e271a2, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田针对急性遗传性血管性水肿发作的治疗药物飞泽优®获批，保障中国HAE患者生命安全, objectType=article, longId=209352, objectId=229a20935293, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=229a20935293, replyNumber=0, likeNumber=37, createdTime=2021-04-04, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=229a20935293, moduleTitle=武田针对急性遗传性血管性水肿发作的治疗药物飞泽优®获批，保障中国HAE患者生命安全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=229a20935293)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517270, encodeId=60f1151e27014, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田和IDT为强生COVID-19疫苗生产提供支持, objectType=article, longId=208551, objectId=2472208551a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2472208551a5, replyNumber=0, likeNumber=49, createdTime=2021-03-19, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2472208551a5, moduleTitle=武田和IDT为强生COVID-19疫苗生产提供支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2472208551a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517269, encodeId=f0a9151e269e1, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田将收购Maverick Therapeutics，以推进T细胞接合治疗实体瘤，扩大新型免疫肿瘤产品组合, objectType=article, longId=208266, objectId=376920826667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=376920826667, replyNumber=0, likeNumber=40, createdTime=2021-03-13, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=376920826667, moduleTitle=武田将收购Maverick Therapeutics，以推进T细胞接合治疗实体瘤，扩大新型免疫肿瘤产品组合, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=376920826667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517267, encodeId=541b151e26724, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果, objectType=article, longId=206667, objectId=b05220666ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b05220666ed0, replyNumber=0, likeNumber=30, createdTime=2021-02-04, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b05220666ed0, moduleTitle=武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b05220666ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517268, encodeId=2c16151e26882, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田完成向Hypera Pharma出售部分OTC产品和非核心资产, objectType=article, longId=206665, objectId=206820666504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=206820666504, replyNumber=0, likeNumber=61, createdTime=2021-02-04, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=206820666504, moduleTitle=武田完成向Hypera Pharma出售部分OTC产品和非核心资产, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=206820666504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517266, encodeId=f03f151e266c9, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田2020年实现碳中和, objectType=article, longId=206427, objectId=ce4b20642ee9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4b20642ee9, replyNumber=0, likeNumber=36, createdTime=2021-01-31, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4b20642ee9, moduleTitle=武田2020年实现碳中和, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4b20642ee9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517265, encodeId=ae2f151e26579, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田高血压新药「美阿沙坦钾片」在中国获批上市, objectType=article, longId=206131, objectId=1540206131de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1540206131de, replyNumber=0, likeNumber=39, createdTime=2021-01-24, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1540206131de, moduleTitle=武田高血压新药「美阿沙坦钾片」在中国获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1540206131de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517264, encodeId=d68a151e26436, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田在J.P. Morgan Healthcare第39届年会上介绍产品线更新和分享2030财年营收增幅达50%的目标, objectType=article, longId=205739, objectId=4d54205e3900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d54205e3900, replyNumber=0, likeNumber=48, createdTime=2021-01-16, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d54205e3900, moduleTitle=武田在J.P. Morgan Healthcare第39届年会上介绍产品线更新和分享2030财年营收增幅达50%的目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d54205e3900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517263, encodeId=efbd151e263b5, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田完成向Cheplapharm出售部分非核心资产, objectType=article, longId=205404, objectId=4db720540488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4db720540488, replyNumber=0, likeNumber=51, createdTime=2021-01-08, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4db720540488, moduleTitle=武田完成向Cheplapharm出售部分非核心资产, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4db720540488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517262, encodeId=c510151e262d4, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=美国FDA核准武田ICLUSIG® (ponatinib)用于耐药或不耐受慢性期CML成人患者的补充新药申请, objectType=article, longId=204831, objectId=316c204831cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=316c204831cf, replyNumber=0, likeNumber=38, createdTime=2020-12-25, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=316c204831cf, moduleTitle=美国FDA核准武田ICLUSIG® (ponatinib)用于耐药或不耐受慢性期CML成人患者的补充新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=316c204831cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517261, encodeId=d92e151e26146, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=FDA批准武田的ICLUSIG（ponatinib）治疗耐药或不耐药的慢性粒细胞白血病, objectType=article, longId=204700, objectId=ab45204e0089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab45204e0089, replyNumber=0, likeNumber=51, createdTime=2020-12-21, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab45204e0089, moduleTitle=FDA批准武田的ICLUSIG（ponatinib）治疗耐药或不耐药的慢性粒细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab45204e0089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517260, encodeId=af2e151e260eb, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田中国首届罕见病患者交流峰会成功召开赋能患者组织成长, objectType=article, longId=200825, objectId=54a1200825e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54a1200825e0, replyNumber=0, likeNumber=39, createdTime=2020-09-19, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54a1200825e0, moduleTitle=武田中国首届罕见病患者交流峰会成功召开赋能患者组织成长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54a1200825e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517259, encodeId=34d5151e259da, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田瑞普佳® （阿加糖酶α注射用浓溶液）获批进入中国，为法布雷病患者带来更多治疗选择, objectType=article, longId=200017, objectId=3eb520001ea0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eb520001ea0, replyNumber=0, likeNumber=37, createdTime=2020-08-30, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eb520001ea0, moduleTitle=武田瑞普佳® （阿加糖酶α注射用浓溶液）获批进入中国，为法布雷病患者带来更多治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eb520001ea0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517258, encodeId=6c72151e25835, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, objectType=article, longId=194626, objectId=133519462630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133519462630, replyNumber=0, likeNumber=21, createdTime=2020-05-25, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133519462630, moduleTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133519462630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517257, encodeId=d3f5151e257dc, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris, objectType=article, longId=194236, objectId=13fa194236c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13fa194236c3, replyNumber=0, likeNumber=52, createdTime=2020-05-17, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13fa194236c3, moduleTitle=欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13fa194236c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517256, encodeId=a756151e25603, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=淋巴瘤患者治疗新选择：武田靶向CD30的创新抗体偶联药物（注射用维布妥昔单抗）正式获批 , objectType=article, longId=194204, objectId=9ef5194204f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ef5194204f6, replyNumber=0, likeNumber=54, createdTime=2020-05-17, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ef5194204f6, moduleTitle=淋巴瘤患者治疗新选择：武田靶向CD30的创新抗体偶联药物（注射用维布妥昔单抗）正式获批 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ef5194204f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517255, encodeId=eb59151e255fd, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定, objectType=article, longId=193124, objectId=e57a19312429, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e57a19312429, replyNumber=0, likeNumber=39, createdTime=2020-04-30, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e57a19312429, moduleTitle=治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e57a19312429)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517254, encodeId=d46d151e25425, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, objectType=article, longId=191689, objectId=a505191689b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a505191689b3, replyNumber=0, likeNumber=19, createdTime=2020-04-09, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a505191689b3, moduleTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a505191689b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

武田

2020-05-29

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田2020财年业绩保持韧性，利润率和现金流均表现强劲；基础营收增长预计在2021财年加速

2021-05-20

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田宣布美国FDA将优先审理Mobocertinib (TAK-788)治疗EGFR外显子20插入+转移性非小细胞肺癌的新药报批

2021-05-01

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田针对急性遗传性血管性水肿发作的治疗药物飞泽优®获批，保障中国HAE患者生命安全

2021-04-04

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田和IDT为强生COVID-19疫苗生产提供支持

2021-03-19

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田将收购Maverick Therapeutics，以推进T细胞接合治疗实体瘤，扩大新型免疫肿瘤产品组合

2021-03-13

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果

2021-02-04

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田完成向Hypera Pharma出售部分OTC产品和非核心资产

2021-02-04

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田2020年实现碳中和

2021-01-31

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田高血压新药「美阿沙坦钾片」在中国获批上市

2021-01-24

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田在J.P. Morgan Healthcare第39届年会上介绍产品线更新和分享2030财年营收增幅达50%的目标

2021-01-16

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田完成向Cheplapharm出售部分非核心资产

2021-01-08

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

美国FDA核准武田ICLUSIG® (ponatinib)用于耐药或不耐受慢性期CML成人患者的补充新药申请

2020-12-25

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

FDA批准武田的ICLUSIG（ponatinib）治疗耐药或不耐药的慢性粒细胞白血病

2020-12-21

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田中国首届罕见病患者交流峰会成功召开赋能患者组织成长

2020-09-19

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田瑞普佳® （阿加糖酶α注射用浓溶液）获批进入中国，为法布雷病患者带来更多治疗选择

2020-08-30

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者

2020-05-25

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris

2020-05-17

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

淋巴瘤患者治疗新选择：武田靶向CD30的创新抗体偶联药物（注射用维布妥昔单抗）正式获批

2020-05-17

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定

2020-04-30

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物

2020-04-09

科室
- - 订阅+
  - 更多科室
工具
服务